Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease
Javier Pagonabarraga, Rocío Pérez‐González, Helena Bejr‐Kasem, et al.
Parkinsonism & Related Disorders (2022) Vol. 105, pp. 132-138
Closed Access | Times Cited: 18

Showing 18 citing articles:

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
Lucia Batzu, Silvia Rota, Abdul Hye, et al.
npj Parkinson s Disease (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 37
How should we be using biomarkers in trials of disease modification in Parkinson’s disease?
Nirosen Vijiaratnam, Thomas Foltynie
Brain (2023) Vol. 146, Iss. 12, pp. 4845-4869
Open Access | Times Cited: 18
Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative
Erlan Sanchez, Tim Wilkinson, Gillian Coughlan, et al.
Alzheimer s & Dementia (2023) Vol. 20, Iss. 3, pp. 1753-1770
Open Access | Times Cited: 16
Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease
Andrea Pilotto, Nicholas J. Ashton, Alessandro Lupini, et al.
Journal of Neurology (2024)
Open Access | Times Cited: 6
Parkinson’s disease therapy: what lies ahead?
Andreas Wolff, Nicolas U Schumacher, Dominik Pürner, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 793-820
Open Access | Times Cited: 13
How to advance the pharmacological management of cognitive impairment in Parkinson's disease
Carla Abdelnour, Lucy L. Gibson, Lucia Batzu, et al.
Journal of Parkinson s Disease (2025)
Open Access
Mild cognitive impairment in Parkinson's disease: current view
K. A. Jellinger
Frontiers in Cognition (2024) Vol. 3
Open Access | Times Cited: 4
Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
Yasuaki Mizutani, Reiko Ohdake, Harutsugu Tatebe, et al.
Journal of Neurology (2023) Vol. 270, Iss. 11, pp. 5461-5474
Open Access | Times Cited: 10
Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease
Carla Abdelnour, Christina B. Young, Marian Shahid, et al.
Annals of Neurology (2024) Vol. 96, Iss. 3, pp. 526-538
Open Access | Times Cited: 3
Prediction of Cognitive Heterogeneity in Parkinson's Disease: A 4‐Year Longitudinal Study Using Clinical, Neuroimaging, Biological and Electrophysiological Biomarkers
Arnau Puig‐Davi, Saül Martínez‐Horta, Laura Pérez‐Carasol, et al.
Annals of Neurology (2024) Vol. 96, Iss. 5, pp. 981-993
Open Access | Times Cited: 3
Neuroimaging and plasma evidence of early white matter loss in Parkinson’s disease with poor outcomes
Angeliki Zarkali, Naomi Hannaway, Peter McColgan, et al.
Brain Communications (2024) Vol. 6, Iss. 3
Open Access | Times Cited: 2
Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses
Elisa Mantovani, Alice Martini, Alessandro Dinoto, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Plasma pTau181 reveals a pathological signature that predicts cognitive outcomes in Lewy body disease
Carla Abdelnour, Christina B. Young, Marian Shahid, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Alzheimer’s Disease Related Biomarkers Were Associated with Amnestic Cognitive Impairment in Parkinson’s Disease: A Cross-Sectional Cohort Study
Xiaofan Xue, Shanshan Mei, Anqi Huang, et al.
Brain Sciences (2024) Vol. 14, Iss. 8, pp. 787-787
Open Access
Plasma Phosphorylated Tau181 and Amyloid-β42 in Dementia with Lewy Bodies Compared with Alzheimer’s Disease and Cognitively Healthy People
Yueyi Yu, Xinyi Xia, Xiaosheng Meng, et al.
Journal of Alzheimer s Disease (2023) Vol. 95, Iss. 1, pp. 161-169
Closed Access | Times Cited: 1
Serum levels of p-tau181 in patients with Parkinson’s disease
Zhanglin Tian, Long Bo, Mi Xiong, et al.
International Journal of Biology and Life Sciences (2023) Vol. 2, Iss. 2, pp. 19-23
Open Access
Neuroimaging and plasma marker evidence for white matter macrostructure loss in Parkinson’s disease
Angeliki Zarkali, Naomi Hannaway, Peter McColgan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Utility of serum neurofilament light chain and glial fibrillary acidic protein as diagnostic biomarkers of freezing of gait in Parkinson’s disease
Xu Liu, Xuanjing Liu, Yuning Liu, et al.
Brain Research (2023) Vol. 1822, pp. 148660-148660
Closed Access
Page 1

Scroll to top